Osmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadership Team

Rhea-AI Summary

Osmotica Pharmaceuticals announced that J. Aaron Green will join RVL Pharmaceuticals as Vice President of Sales and Market Development, effective July 6, 2021. Aaron brings over 20 years of experience in eye care and medical aesthetics, previously serving in leadership roles at Galderma and Alcon Laboratories. His appointment is seen as a strategic move to bolster RVL's growth in ocular aesthetics and expand the market for UPNEEQ. Brian Markison, CEO, expressed confidence in Aaron's capabilities to enhance organizational strength during this pivotal growth period.

Positive

• Appointment of J. Aaron Green expected to strengthen sales and market development.
• Aaron has over 20 years of relevant industry experience, enhancing leadership capabilities.
• The move is aimed at expanding the market for UPNEEQ, indicating strategic growth.

Negative

• None.

BRIDGEWATER, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that J. Aaron Green will join the leadership team of RVL Pharmaceuticals, Inc. (“RVL”), the Company’s wholly owned subsidiary focused on eye care and ocular aesthetics, in the role of Vice President, Sales and Market Development, Aesthetics, effective July 6, 2021.

“I’m thrilled to welcome Aaron to the leadership team at RVL, as he will help expand and strengthen our organization during this time of what we believe will be unprecedented growth. Under the leadership of Ryan Bleeks, VP Sales, Eye Care, we recently completed the expansion of our eye care team and have now added another accomplished executive to the growing RVL organization,” said Brian Markison, Chairman and Chief Executive Officer of Osmotica.

“I am excited to join RVL at this pivotal point in their evolution and partner with the rest of the team as we build a new market and bring this novel treatment to the millions of patients with droopy eyelids,” stated Mr. Green.

J. Aaron Green joins RVL with over 20 years of experience across eye care and medical aesthetics. Most recently, Mr. Green was a commercial leader at Galderma for eight years, with a track record of commercial success that spans both domestic and international initiatives. Prior to Galderma, Mr. Green held marketing and sales roles for Alcon Laboratories for 14 years, where he also led commercial operations of the pharmaceutical business in 31 domestic and international markets with over $250 million in annual revenue.

“This is yet another positive step for the organization as we continue to invest in the future of UPNEEQ^® and build a market in ocular aesthetics,” concluded Markison.

About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ^®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.

Osmotica has operations in the United States and Hungary.

Forward Looking Statements

This press release includes statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” The Company’s actual results may vary significantly from the results anticipated in these forward-looking statements, which can generally be identified by the use of forward-looking terminology, including the terms “believes,” “expects,” “may,” “will,” “should,” “seeks,” “projects,” “approximately,” “intends,” “plans,” “estimates” or “anticipates,” or, in each case, their negatives or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They include statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, its results of operations, financial condition, liquidity, prospects, financial guidance, growth plan, strategies, trends and other events, particularly relating to sales of current products and the development, approval and introduction of new products, FDA and other regulatory applications, approvals and actions, the continuation of historical trends, and the sufficiency of our cash balances and cash generated from operating and financing activities for future liquidity and capital resource needs. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place significant reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Important factors that could cause actual results and events to differ materially from those indicated in the forward-looking statements include the following: our dependence on a limited number of products; our ability to successfully develop or commercialize new products, or do so on a timely or cost effective basis; failures of or delays in clinical trials or other delays in obtaining regulatory approval or commencing product sales for new products; the impact of legal proceedings; the Company’s ability to service its substantial debt; the Company’s ability to raise additional capital; the impact of competition from both brand and generic companies; any interruption at the Company’s manufacturing facility, warehouses or at facilities operated by third parties that the Company relies on for our products; the Company’s dependence on major customers; the Company’s ability to develop and maintain our sales capabilities; the impact of any litigation related to allegations of infringement of intellectual property; any changes to the coverage and reimbursement levels for its products by governmental authorities and other third-party payors as a result of healthcare reform or otherwise; the impact of any changes in the extensive governmental regulation that the Company faces; manufacturing or quality control issues that the Company may face; and other risks and uncertainties more fully described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2020 and other filings that the Company makes with the Securities and Exchange Commission. These forward-looking statements speak only as of the time of this release and we do not undertake to publicly update or revise them, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Relations for Osmotica Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com 

FAQ

Who is J. Aaron Green and what will his role be at Osmotica?

J. Aaron Green will serve as Vice President of Sales and Market Development at RVL Pharmaceuticals, effective July 6, 2021.

What is the significance of J. Aaron Green's appointment for Osmotica?

His appointment is intended to strengthen the leadership team and drive growth in ocular aesthetics, particularly for the product UPNEEQ.

What experience does J. Aaron Green bring to the position?

He has over 20 years of experience in eye care and medical aesthetics, with notable leadership roles at Galderma and Alcon.

What are the future prospects for Osmotica following this leadership change?

The company aims for unprecedented growth in ocular aesthetics under Green's leadership, enhancing market potential for their products.